Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note released on Thursday morning. The firm issued a hold rating on the stock.

A number of other brokerages have also issued reports on EKSO. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Ekso Bionics in a research report on Tuesday, March 4th. Lake Street Capital decreased their price objective on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th.

Ekso Bionics Price Performance

Shares of EKSO opened at $0.44 on Thursday. Ekso Bionics has a 52 week low of $0.34 and a 52 week high of $1.53. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The firm has a market cap of $10.89 million, a price-to-earnings ratio of -0.67 and a beta of 1.43. The stock has a 50 day moving average of $0.52 and a 200-day moving average of $0.75.

Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Monday, March 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The company had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. As a group, analysts forecast that Ekso Bionics will post -0.48 EPS for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.